Global Pediatric Epilepsy Therapeutics Market 2019-2023
About this market
The emergence of biomarkers to gain traction in the market. The world of epilepsy diagnostics is experiencing a trend of emerging biomarkers for epileptogenesis. Epilepsy is the disorder of repeated seizures; hence, these biomarkers for epileptogenesis are used to identify the spontaneity of the seizures. Technavio’s analysts have predicted that the pediatric epilepsy therapeutics market will register a CAGR of close to 6% by 2023.
Increasing demand for second and third-generation AEDs
The global pediatric epilepsy therapeutics market is witnessing a surge in the number of second-generation AEDs such as felbamate, lamotrigine, as they have low interaction and propensity for cognitive side-effects.
Adverse side effects and increasing social stigma
The global pediatric epilepsy therapeutics market has many approved drugs; however, they are associated with major side effects.
For the detailed list of factors that will drive and challenge the growth of the pediatric epilepsy therapeutics market during the 2019-2023, view our report.
The market appears to be fragmented and with the presence of several companies including Eisai and GlaxoSmithKline the competitive environment is quite intense. Factors such as the emergence of biomarkers and the increasing demand for second and third-generation AEDs, will provide considerable growth opportunities to pediatric epilepsy therapeutics manufactures. Eisai, GlaxoSmithKline, Pfizer, UCB, and GW Pharmaceuticals are some of the major companies covered in this report.
‘With the presence of a considerable number of companies, this market appears to be fragmented. Some of the leading pediatric epilepsy therapeutic companies are forming alliances with organizations and vendors to develop therapeutics that a novel mechanism to make a smoother market entry.’
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook